- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07815353
ECHO-COPD: Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention Among Chronic Obstructive Pulmonary Disease Patients (ECHO-COPD)
Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention on Medication Adherence, Quality of Life, and Direct Costs in Patients With Chronic Obstructive Pulmonary Disease: A Quasi-Experimental Study
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease associated with substantial morbidity and mortality, impaired quality of life, and healthcare costs. Medication adherence and appropriate self-management are important components of COPD management; however, patients' health beliefs and perceptions may influence their adherence to treatment and engagement in recommended health behaviours. This study aims to evaluate the impact of a pharmacist-led educational intervention based on the Health Belief Model (HBM) on medication adherence, quality of life, and direct healthcare costs among patients with COPD receiving care at Buraidah Central Hospital (BCH) in Al-Qassim Region, Saudi Arabia. This study will use a quantitative, quasi-experimental pretest-posttest control-group design. Eligible COPD patients will be non-randomly assigned to either an intervention group or a control group. The intervention group will receive structured, pharmacist-led HBM-based educational sessions in addition to routine care. In contrast, the control group will receive standard care without additional education. Baseline assessments will include medication adherence using the Morisky Medication Adherence Scale-8 (MMAS-8); quality of life and health status using the COPD Assessment Test (CAT); health beliefs using a structured HBM questionnaire; and direct medical costs obtained from the hospital clinical cost centre. The educational intervention will be delivered over six months, followed by post-intervention assessment using the same outcome measures.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The Health Belief Model (HBM) will guide the content and delivery of the pharmacist-led educational intervention. The intervention will address six core HBM constructs: perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cues to action, and self-efficacy. The purpose of applying the HBM is to improve patients' understanding of chronic obstructive pulmonary disease (COPD) and promote positive behavioural changes, particularly improved medication adherence.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Bander S Alshammeri, MSc
- Telefoonnummer: +966509466669
- E-mail: bandershe3@gmail.com
Studie Contact Back-up
- Naam: Rabia Hussain, PhD, Lecturer
- Telefoonnummer: +6046534085
- E-mail: rabia.hussain@usm.my
Studie Locaties
-
-
Al-Qassim Region
-
Buraidah, Al-Qassim Region, Saoedi-Arabië, 52391
- Bander S Alshammeri
-
Contact:
- Bander S Alshammeri, MSc
- Telefoonnummer: +966509466669
- E-mail: bandershe3@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Participants must:
- Be adults aged 18-65 years.
- Be diagnosed with chronic obstructive pulmonary disease (COPD) stages I-III according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.
- Have visited or been admitted for a COPD exacerbation and are receiving care at Buraidah Central Hospital (BCH) in Al-Qassim Region, Saudi Arabia.
- Be Arabic-speaking and capable of understanding study instructions.
- Be willing and able to provide written informed consent.
Exclusion Criteria:
Participants will be excluded if they:
- Are diagnosed with COPD stage IV.
- Have another significant pulmonary disease, including: Asthma, bronchiectasis, pneumonia, or cystic fibrosis.
- Have a serious systemic illness, severe comorbidity, or central organ dysfunction, including: Hepatic dysfunction, renal dysfunction, psychiatric impairment or sensory impairment.
- Are immunocompromised or receiving immunosuppressive treatment.
- Have psychological, sensory, or cognitive impairment that prevents meaningful participation in the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: HBM-Based Educational Intervention
Participants in the intervention group will receive routine care together with structured pharmacist-led educational sessions based on the HBM. The educational intervention will be conducted face-to-face during scheduled outpatient appointments in the designated counselling room of the Pulmonary Department. The programme will be delivered from study months 4 to 9. Educational sessions will include:
|
Participants in the intervention group will receive routine care together with structured pharmacist-led educational sessions based on the HBM. The educational intervention will be conducted face-to-face during scheduled outpatient appointments in the designated counselling room of the Pulmonary Department. The programme will be delivered from study months 4 to 9. Educational sessions will include:
|
|
Geen tussenkomst: Standard Care
Participants in the control group will continue to receive routine/standard care provided by BCH. They will not receive the additional structured pharmacist-led HBM-based educational intervention. Both intervention and control participants will undergo the same baseline and post-intervention assessments. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Medication Adherence
Tijdsspanne: Baseline and 6 months after initiation of the educational intervention.
|
Outcome Measure: Change in Medication Adherence Assessed by the Morisky Medication Adherence Scale-8. Measurement Tool: Morisky Medication Adherence Scale-8 (MMAS-8), prevalidated Arabic version. The MMAS-8 is an 8-item self-reported measure of medication-taking behaviour, with a total score ranging from 0 to 8. Higher scores indicate better medication adherence, whereas lower scores indicate poorer adherence. Scores are commonly classified as low adherence (<6), medium adherence (6 to <8), and high adherence (8). |
Baseline and 6 months after initiation of the educational intervention.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Quality of Life and Health Status
Tijdsspanne: Baseline and 6 months after initiation of the educational intervention.
|
Outcome Measure: Change in Health Status Assessed by the COPD Assessment Test (CAT). Description: The prevalidated Arabic COPD Assessment Test (CAT) will be used to assess health status in patients with chronic obstructive pulmonary disease. The CAT contains 8 items, each scored from 0 to 5, giving a total score range of 0-40. Higher scores indicate a greater impact of COPD on health status and therefore a worse outcome; lower scores indicate better health status. |
Baseline and 6 months after initiation of the educational intervention.
|
|
Direct Healthcare Costs
Tijdsspanne: Direct medical costs assessed during the pre-intervention baseline period and during the post-intervention follow-up period after completion of the six-month intervention.
|
Change in direct medical costs associated with COPD Direct healthcare cost data will be obtained from the clinical cost centre of Buraidah Central Hospital (BCH). The costing analysis will include direct COPD-related healthcare resources such as:
Important Costing Specification The cost of delivering the educational intervention will not be included in the costing analysis. The economic component of this study focuses on the direct cost of illness associated with COPD rather than the cost of implementing the educational intervention. |
Direct medical costs assessed during the pre-intervention baseline period and during the post-intervention follow-up period after completion of the six-month intervention.
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
HBM Constructs
Tijdsspanne: Baseline and 6 months after initiation of the educational intervention.
|
Outcome Measure: Change in Health Beliefs Assessed by the Health Belief Model (HBM) Questionnaire. Description: A prevalidated Arabic Health Belief Model (HBM) questionnaire will assess six constructs using a 3-point Likert scale (Disagree=0, Neutral=1, Agree=2). Perceived susceptibility: 3 items, range 0-6; severity: 5 items, 0-10; benefits: 3 items, 0-6; barriers: 5 items, 0-10; cues to action: 5 items, 0-10; self-efficacy: 5 items, 0-10. Higher scores indicate greater levels of the respective construct. For perceived barriers, higher scores indicate more barriers and therefore a less favourable outcome. |
Baseline and 6 months after initiation of the educational intervention.
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Chronische ziekte
- Ziekte attributen
- Ziekten van de luchtwegen
- Longziekten
- Longziekten, obstructief
- Pathologische aandoeningen, tekenen en symptomen
- Gedrag
- Therapietrouw en therapietrouw
- Gezondheidsgedrag
- Naleving van de patiënt
- Patiëntacceptatie van gezondheidszorg
- Longziekte, chronisch obstructief
- Medicatie therapietrouw
Andere studie-ID-nummers
- USM-DSAP-2026-002
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .